About jim

This author has not yet filled in any details.
So far jim has created 24 blog entries.

CEO Letter to Shareholders: 2015 Results Expand Therapy Options for Concussion

Dear Shareholders: Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation.  The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only.  Concussion is a growing issue [...]

2018-05-07T18:00:52+00:00 November 5th, 2015|

Vitro Biopharma Launches New Bioanalytical Services and Novel Stem Cell-derived Renal & Neural Cells

Golden, Colorado—September  22, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its product/service offerings to include biomarker profiling services and stem cell derived neuronal and renal cells. Vitro Biopharma’s new services include simultaneous determination of several molecules through multi-plexed assays.  The cells of our bodies communicate with each other through the [...]

2018-05-07T18:00:52+00:00 September 25th, 2015|

Vitro Biopharma Announces Advancement of its Traumatic Brain Injury Clinical Trial & a Favorable Ruling from the FDA

Golden, Colorado—September 2, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in clinical applications of its products and a favorable ruling by the FDA regarding this trial.  The Company’s phase I clinical trial consists of combining two previously FDA-approved drugs in a novel manner to treat TBI including concussion by regeneration of [...]

2018-05-07T18:00:52+00:00 September 3rd, 2015|

Vitro Biopharma Launches MSC-derived Cardiac and Neural Cells for Pre-clinical Toxicology Testing

Golden, Colorado—June 2, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the commercial launch of cardiac and neural cells that are differentiated from human MSCs.  Our new products include cardiomyocytes, alpha motor neurons and neural stem cells.  In support of this commercial launch, we have also launched an improved and updated website featuring [...]

2018-05-07T18:00:52+00:00 June 8th, 2015|

Vitro Biopharma Expands Capacity to Meet Increased Demand for MSC-Gro™ Stem Cell Culture Media

Golden, Colorado—April 29, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of manufacturing capacity based on a recent orders for bulk quantities of  its MSC-Gro ™ Brand of stem cell growth media. Increased demand comes from sales to stem cell researchers and a new customer who recently qualified our media for use [...]

2018-05-07T18:00:52+00:00 April 29th, 2015|

Vitro Biopharma Announces Advances in Clinical Application of Stem Cell Therapy for Neurological Conditions

Golden, Colorado—February 18, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced advances in its stem cell products and services that enhance opportunities to expand clinical studies of stem cell therapy of neurological conditions.  We have previously announced a pre-clinical study of our human MSCs for treatment of stroke in animals that showed near [...]

2018-05-07T18:00:52+00:00 February 18th, 2015|

Stem Cell Therapy of Stroke: Current Research Support and Clinical Studies

Adult stem cell therapy is a common FDA-approved procedure for treatment of blood disorders including leukemia, lymphoma and autoimmune diseases.  Cell therapy using other types of adult stem cells including mesenchymal stem cells (MSCs), neural stem cells (NSCs) and muscle stem cells (Satellite cells) is supported by research findings and proof-of-principle clinical trials but this [...]

2018-05-07T18:00:53+00:00 February 17th, 2015|

Alternatives to Stem Cell Transplants Supported by Key Medical Breakthroughs of 2014

Golden, Colorado—January 13, 2015 —Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced the growing scientific support for use of stem cells that reside within the body for therapeutic and performance enhancement.  A key medical advance of 2014 was research published by scientists at Stanford University and Harvard University regarding mechanisms underlying “parabiosis”, the well-known [...]

2018-05-07T18:00:53+00:00 January 13th, 2015|

Efficacy of Stem Cell Therapy for Stroke Demonstrated in Landmark Study using Vitro Biopharma Stem Cells & Media

Golden, Colorado—September 9, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the publication of a research study using its stem cells to treat an animal model of stroke.  University of Illinois College of Medicine at Peoria (UICOMP) researchers, led by Dr. Krishna Kumar Veeravalli recently published a study showing a prominent reduction in brain [...]

2018-05-07T18:00:53+00:00 September 9th, 2014|

Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America

Golden, Colo.—July 9, 2014—Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies’ commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated. [...]

2018-05-07T18:00:53+00:00 July 28th, 2014|